drug costs

June 8, 2023

Study finds Mark Cuban’s Cost Plus Drug Company could save taxpayers millions on Medicare generic oncology drugs

Vanderbilt research finds that the U.S. government could save taxpayers between $228 million-$2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban Cost Plus Drug Company.

By Craig Boerner
February 9, 2023

Mark Cuban pharmacy could save billions on prostate cancer, bladder drugs

Vanderbilt research found that a new drug company founded by entrepreneur Mark Cuban could save patients $1.29 billion a year based on 2020 Medicare Part D expenditures on just the nine most popular urological drugs.

By Craig Boerner
Stacie Dusetzina, PhD, right, on the South Lawn of the White House with colleagues Rachel Sachs, JD, MPH, of Washington University St. Louis, left, and Michell Mello, PhD, of Stanford.
November 3, 2022

Researcher’s decade of analyzing the price of drugs leads to big reforms

Vanderbilt’s Stacie Dusetzina, PhD, and several colleagues were able to reflect recently on the South Lawn of the White House about how their contributions through research and data informed the provisions in the Inflation Reduction Act that will save older Americans on Medicare tens of thousands of dollars in out-of-pocket costs each year.

By Jake Lowary
May 10, 2022

New study illustrates how much it would cost for cancer drugs covered under Medicare Part D

A new study by Vanderbilt researchers highlights how some older Americans diagnosed with cancer can face unlimited out-of-pocket spending for prescription drugs under the current structure of the Medicare Part D benefit.

By Jake Lowary
January 6, 2022

Study finds sexual minority communities disproportionately engage in behaviors to reduce medication costs

Vanderbilt research finds that individuals from sexual minority populations, including members of the lesbian, gay, bisexual and queer communities, are more likely than heterosexual individuals to engage in behaviors to reduce medication costs.

By Jill Clendening
August 9, 2018

Study to explore how rising medication costs impact elderly

As both drug prices and out-of-pocket expense for prescription medications continue to climb, a team of Health Policy experts at Vanderbilt University School of Medicine (VUSM) have received a grant to determine if these factors are causing older Americans enrolled in Medicare Part D for medication coverage to delay or never fill their prescriptions.

By Jill Clendening
May 9, 2018

Study finds generic options offer limited savings for expensive drugs

Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released this week.
By Craig Boerner